Angeliki Magklara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8812622/publications.pdf

Version: 2024-02-01

45 papers

2,384 citations

201658 27 h-index 42 g-index

46 all docs

46 docs citations

times ranked

46

2567 citing authors

#	Article	IF	CITATIONS
1	Anti-Cancer Properties of Stevia rebaudiana; More than a Sweetener. Molecules, 2022, 27, 1362.	3.8	22
2	Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic Rull-Ptll complexes bridged with 2, 2′-bipyrimidine. Journal of Inorganic Biochemistry, 2021, 219, 111435.	3.5	7
3	Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. Biomedicines, 2021, 9, 1368.	3.2	9
4	Development and Validation of a Targeted †Liquid†MGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2375.	2.6	3
5	Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?. Cancers, 2019, 11, 1573.	3.7	17
6	The Histone Demethylase LSD1/ \hat{l} šDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. Cancers, 2019, 11, 1585.	3.7	47
7	The Basis for Strain-Dependent Rat Aldehyde Dehydrogenase 1A7 (<i>ALDH1A7</i>) Gene Expression. Molecular Pharmacology, 2019, 96, 655-663.	2.3	1
8	Plasma ctDNA RAS mutation analysis by digital polymerase chain reaction in patients with inoperable pancreatic cancer. Annals of Oncology, 2019, 30, vii12.	1.2	0
9	Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Updated results of an observational study. Annals of Oncology, 2019, 30, vii13.	1.2	O
10	LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target. Cancers, 2019, 11, 1821.	3.7	72
11	Soft X-Ray Tomography Reveals Gradual Chromatin Compaction and Reorganization during Neurogenesis InÁVivo. Cell Reports, 2016, 17, 2125-2136.	6.4	85
12	Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers, 2015, 7, 2183-2200.	3.7	28
13	Deep Sequencing Reveals New Aspects of Progesterone Receptor Signaling in Breast Cancer Cells. PLoS ONE, 2014, 9, e98404.	2.5	12
14	Heterochromatin-Mediated Gene Silencing Facilitates the Diversification of Olfactory Neurons. Cell Reports, 2014, 9, 884-892.	6.4	57
15	Stochastic gene expression in mammals: lessons from olfaction. Trends in Cell Biology, 2013, 23, 449-456.	7.9	74
16	Neurons expressing trace amine-associated receptors project to discrete glomeruli and constitute an olfactory subsystem. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13410-13415.	7.1	88
17	Epigenetics and Human Disease. , 2012, , 253-279.		2
18	An Epigenetic Signature for Monoallelic Olfactory Receptor Expression. Cell, 2011, 145, 555-570.	28.9	257

#	Article	IF	CITATIONS
19	High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation. Genome Research, 2011, 21, 1249-1259.	5.5	61
20	HDAC Activity Is Required for Efficient Core Promoter Function at the Mouse Mammary Tumor Virus Promoter. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	8
21	A Composite Intronic Element Directs Dynamic Binding of the Progesterone Receptor and GATA-2. Molecular Endocrinology, 2009, 23, 61-73.	3.7	36
22	Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. Journal of Biological Chemistry, 2005, 280, 14628-14635.	3.4	137
23	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Advances in Clinical Chemistry, 2005, 39, 11-79.	3.7	58
24	Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. International Journal of Cancer, 2004, 108, 588-591.	5.1	36
25	Complex formation between human kallikrein 13 and serum protease inhibitors. Clinica Chimica Acta, 2004, 339, 157-167.	1.1	26
26	Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochemical and Biophysical Research Communications, 2003, 307, 948-955.	2.1	134
27	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. British Journal of Cancer, 2002, 87, 1294-1300.	6.4	42
28	Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. International Journal of Cancer, 2002, 100, 507-514.	5.1	43
29	Ethnic variation in kallikrein expression in nipple aspirate fluid. International Journal of Cancer, 2002, 100, 678-682.	5.1	13
30	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1558-1561.	3.6	31
31	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1558-1561.	3.6	6
32	Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Research and Treatment, 2000, 59, 263-270.	2.5	54
33	Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?. Breast Cancer Research and Treatment, 2000, 60, 1-8.	2.5	4
34	Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. British Journal of Cancer, 2000, 82, 361-367.	6.4	52
35	Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. Clinical Chemistry, 2000, 46, 859-862.	3.2	27
36	Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen. Journal of Clinical Oncology, 2000, 18, 1036-1036.	1.6	99

#	Article	IF	CITATION
37	KLK12 Is a Novel Serine Protease and a New Member of the Human Kallikrein Gene Family—Differential Expression in Breast Cancer. Genomics, 2000, 69, 331-341.	2.9	84
38	The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family $\mathbf{\hat{a}} \in \mathcal{C}$ genomic characterization, mapping, tissue expression and hormonal regulation. Gene, 2000, 254, 119-128.	2.2	87
39	The New Human Kallikrein Gene Family: Implications in Carcinogenesis. Trends in Endocrinology and Metabolism, 2000, 11, 54-60.	7.1	240
40	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000, 300, 171-180.	1.1	18
41	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology, 2000, 56, 527-532.	1.0	99
42	DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal of Urology, 2000, 163, 802-805.	0.4	15
43	Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid. Clinical Chemistry, 1999, 45, 1774-1780.	3.2	34
44	The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA. Clinical Chemistry, 1999, 45, 1960-1966.	3.2	103
45	Development of an Ultrasensitive Immunoassay for Human Glandular Kallikrein with No Cross-Reactivity from Prostate-specific Antigen. Clinical Chemistry, 1999, 45, 790-799.	3.2	56